The glucagon-like peptide-1 agonists market share for oral products remains modest today, yet pipeline candidates such as GSBR-1290 and danuglipron aim to match injectable efficacy without requiring absorption enhancers
Until such data exist we must be cautious about assumed synergy
T., Yi, P., Li, Y., Hueng, C., & Xiao, W
Appetite suppression often begins before measurable weight loss
Extra weight and insulin resistance reduce GLP-1 secretion as well as beta cell (insulin-secreting cells in the pancreas) responsiveness
Ojo con los posibles efectos adversos En Estados Unidos se han presentado numerosas demandas contra los fabricantes de Ozempic y Mounjaro, alegando que no advirtieron adecuadamente sobre los efectos secundarios graves, como gastroparesia (parlisis gstrica) y otros problemas gastrointestinales severos